Aimmune Therapeutics, Inc.
Aimmune Therapeutics develops treatments to protect people with food allergies from the life-threatening consequences of accidental exposure. The company was founded in 2011 in partnership with Food Allergy Research & Education (FARE), the nation’s leading nonprofit focused on food allergies. AIMT is developing a portfolio of standardized desensitization drug products and protocols for treating food allergy. The company's lead product, AR-101, is aimed at peanut allergy and is currently being tested. In addition to its lead therapeutic candidate, the company also plans to develop products for desensitization to other allergies including egg and milk.
There are currently an estimated two million Americans that are allergic to peanuts, including one million children. Based on these patient numbers, Foresite Capital estimates that the entire market opportunity for AR-101 could exceed $2 billion. AIMT is also developing additional products for egg and other allergens, which in Foresite Capital's view, could represent market opportunities which are similar in size to the peanut allergy market. Foresite Capital believes that AIMT will become a leader in the treatment of patients who suffer from many types of food allergies, which is a growing unmet medical need with limited therapeutic options.